PURPOSE: To examine whether modified radical mastectomy (MRM) improves outcomes compared with breast-conserving treatment (BCT) in young women. METHODS AND MATERIALS: Women aged 20-49 years, diagnosed with early breast cancer between 1989 and 1998, were identified. Management with BCT or MRM was compared for local (L), locoregional (LR), and distant relapse-free survival (DRFS) and breast cancer-specific survival (BCSS) by age group (20-39 years, 40-49 years). The analysis was repeated for patients considered "ideal" candidates for BCT: tumor size < or =2 cm, pathologically negative axillary nodes, negative margins, and no reported ductal carcinoma in situ. RESULTS: A total of 1,597 women received BCT, and 801 had MRM. After a median follow-up of 9.0 years, the outcomes (L, LR, BCSS) were worse for the younger age group; however, the outcomes were not statistically different by type of local treatment. For women aged 20-39 years considered "ideal" for BCT, those treated with BCT had slightly lower LRFS compared with those treated with MRM (p = 0.3), but DRFS and BCSS were similar. CONCLUSIONS: A difference in LRFS at 10 years potentially favored MRM among women aged 20-39 years considered "ideal" BCT candidates but was not statistically significant and did not translate into a noticeable difference in DRFS or BCSS. Our data suggest that young age alone is not a contraindication to BCT.
PURPOSE: To examine whether modified radical mastectomy (MRM) improves outcomes compared with breast-conserving treatment (BCT) in young women. METHODS AND MATERIALS: Women aged 20-49 years, diagnosed with early breast cancer between 1989 and 1998, were identified. Management with BCT or MRM was compared for local (L), locoregional (LR), and distant relapse-free survival (DRFS) and breast cancer-specific survival (BCSS) by age group (20-39 years, 40-49 years). The analysis was repeated for patients considered "ideal" candidates for BCT: tumor size < or =2 cm, pathologically negative axillary nodes, negative margins, and no reported ductal carcinoma in situ. RESULTS: A total of 1,597 women received BCT, and 801 had MRM. After a median follow-up of 9.0 years, the outcomes (L, LR, BCSS) were worse for the younger age group; however, the outcomes were not statistically different by type of local treatment. For women aged 20-39 years considered "ideal" for BCT, those treated with BCT had slightly lower LRFS compared with those treated with MRM (p = 0.3), but DRFS and BCSS were similar. CONCLUSIONS: A difference in LRFS at 10 years potentially favored MRM among women aged 20-39 years considered "ideal" BCT candidates but was not statistically significant and did not translate into a noticeable difference in DRFS or BCSS. Our data suggest that young age alone is not a contraindication to BCT.
Authors: Nils D Arvold; Alphonse G Taghian; Andrzej Niemierko; Rita F Abi Raad; Meera Sreedhara; Paul L Nguyen; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2011-09-06 Impact factor: 44.544
Authors: D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso Journal: Curr Treat Options Oncol Date: 2015-04
Authors: Julia C Radosa; Anne Eaton; Michelle Stempel; Amrin Khander; Cornelia Liedtke; Erich-Franz Solomayer; Maria Karsten; Melissa Pilewskie; Monica Morrow; Tari A King Journal: Ann Surg Oncol Date: 2016-10-25 Impact factor: 5.344
Authors: Beth M Beadle; Wendy A Woodward; Susan L Tucker; Elesyia D Outlaw; Pamela K Allen; Julia L Oh; Eric A Strom; George H Perkins; Welela Tereffe; Tse-Kuan Yu; Funda Meric-Bernstam; Jennifer K Litton; Thomas A Buchholz Journal: Int J Radiat Oncol Biol Phys Date: 2008-08-15 Impact factor: 7.038